XW020D8
Introduction Muscle to New Technology Group 8 with Engineered Allogeneic Thymus Tissue, Open Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 2 Muscle |
| Approach | 0 Open |
| Device | D Engineered Allogeneic Thymus Tissue |
| Qualifier | 8 New Technology Group 8 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Muscle
Muscle tissue, whether skeletal or otherwise, is targeted for Introduction procedures when a New Technology substance is delivered directly into the muscular layer rather than the skin or subcutaneous fat above it. This route is used for agents intended to act locally within muscle or to achieve absorption through a highly vascular tissue bed, and it differs mechanically and pharmacokinetically from more superficial injection routes. Because muscle groups vary widely in size, depth, and blood supply across the body, the specific site chosen can affect both technique and the rate at which the introduced substance takes effect. This code is reserved for substances qualifying as New Technology, such as investigational or recently approved biologic agents, rather than routine intramuscular medications.
Approach: Open
Open approach in New Technology denotes access to the target site through a surgical incision that exposes the body part directly to view and instrumentation. It stands apart from percutaneous and endoscopic approaches, which achieve access through small punctures or existing openings rather than a deliberate surgical opening of tissue.
Device / Substance / Technology: Engineered Allogeneic Thymus Tissue
Engineered allogeneic thymus tissue is a lab-processed donor thymus implant used to treat congenital athymia, a rare condition in which infants are born without a functioning thymus and cannot develop normal T-cell immunity. The tissue is surgically implanted to allow T-cell maturation to occur in the recipient. It is unrelated in mechanism to the monoclonal antibodies and vaccines elsewhere in this list, functioning instead as a structural tissue graft rather than a pharmacologic agent.
Qualifier: New Technology Group 8
Group 8 identifies technologies added to the New Technology section for the 2021-2022 update cycle, tying a given code to that specific approval year. The underlying substance, device, or technique is defined by the other six axis positions, not by the group number itself. Because group numbers simply track chronology, Group 8 differs from Group 7 and Group 9 only in when CMS granted the technology separate recognition.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.